STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeut - OCUL STOCK NEWS

Welcome to our dedicated page for Ocular Therapeut news (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeut stock.

Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical innovator developing sustained-release therapies for retinal diseases and ocular conditions. This page serves as the definitive source for company news, providing investors and professionals with timely updates on clinical advancements, regulatory developments, and corporate milestones.

Access press releases, earnings reports, and analysis of key events impacting OCUL's trajectory. Our curated collection includes updates on AXPAXLI™ clinical trials for wet AMD, DEXTENZA® commercial performance, and pipeline progress across glaucoma and diabetic retinopathy therapies. Discover how the company's proprietary hydrogel platform addresses treatment challenges in ophthalmology.

Bookmark this page for streamlined access to OCUL's latest FDA submissions, partnership announcements, and financial disclosures. Stay informed about developments influencing both near-term performance and long-term growth in ocular therapeutics.

News

Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy

Rhea-AI Summary
Ocular Therapeutix™ announces positive topline Phase 1 data for AXPAXLI™ in diabetic retinopathy, with 46.2% of patients showing improvement in the Diabetic Retinopathy Severity Scale at 40 weeks. AXPAXLI was well-tolerated with no inflammation observed. The company plans to move directly to a Phase 3 study based on the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.69%
Tags
clinical trial
-
News

Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders

Rhea-AI Summary
Ocular Therapeutix strengthens its clinical team by appointing key retinal leaders, including Dr. Nadia K. Waheed as Chief Medical Officer and Dr. Peter K. Kaiser as Chief Development Officer. The company aims to advance its Phase 3 AXPAXLI program for wet AMD and diabetic retinopathy, positioning itself as a leading retina care company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
management
-
News

Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO

Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that Executive Chairman, Pravin U. Dugel, MD, is taking over as President and CEO, with Antony Mattessich stepping down. Dr. Dugel will also continue as a director and Executive Chairman. The company expressed gratitude for Mattessich's service and highlighted the potential of their innovative retinal disease pipeline, particularly AXPAXLI™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
News

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) granted inducement equity awards to its new Senior Vice President, Global Head of Biometrics. The awards include a stock option for 130,000 shares and a restricted stock unit award for 43,333 shares. The awards are part of Ocular's 2019 Inducement Stock Incentive Plan and are subject to specific vesting schedules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News

Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting

Rhea-AI Summary
Ocular Therapeutix, Inc. announces positive Phase 2 data for PAXTRAVA implant in patients with open-angle glaucoma or ocular hypertension. The data show consistent and sustained reductions in Intraocular Pressure (IOP) over six months, with a 24-30% reduction achieved. The implant was well-tolerated, with no impact on corneal health observed. The results indicate potential for repeat dosing without stacking of implants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)

Rhea-AI Summary
Ocular Therapeutix, Inc. announces multiple scientific presentations at the 2024 ASCRS Annual Meeting. The presentations focus on innovative therapies for eye diseases like wet AMD and diabetic retinopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
News

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results

Rhea-AI Summary
Ocular Therapeutix, Inc. reports financial results, leadership appointments, and upcoming milestones. The company aims to be a leader in retinal care with a focus on wet AMD, diabetic retinopathy, and glaucoma treatments. Positive milestones include successful financings, key leadership appointments, and progress in clinical trials. Financially, the company has a strong cash position and increasing revenues. However, there are concerns regarding rising research and development expenses, net losses, and non-cash charges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
earnings
-
News

Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) plans to report its fourth quarter and full year 2023 financial results on March 11, 2024, after 4:00 p.m. Eastern Time. The company will not host a conference call due to recent leadership appointments and a $325 million private placement. A conference call to discuss corporate strategy is scheduled for the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
earnings
-
News

Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer

Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) grants inducement equity awards to Executive Chairman and Chief Strategy Officer, Dr. Pravin U. Dugel and Dr. Sanjay Nayak. The awards include stock options and restricted stock units, with vesting schedules over multiple years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none
News

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Rhea-AI Summary
Ocular Therapeutix, Inc. announces a private placement to raise $325.0 million through the sale of common stock and pre-funded warrants to institutional accredited investors. The funds will be used to accelerate the clinical development of AXPAXLI™ for wet AMD treatment, support other clinical programs, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none
Stock OCUL logo
Ocular Therapeut

Nasdaq:OCUL

OCUL Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

OCUL Stock Data

1.16B
152.15M
1.01%
85.07%
7.58%
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD